Terms: = Sarcomas AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
817 results:
1. Principles in the Management of Glioblastoma.
Roda D; Veiga P; Melo JB; Carreira IM; Ribeiro IP
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674436
[TBL] [Abstract] [Full Text] [Related]
2. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.
Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876
[TBL] [Abstract] [Full Text] [Related]
3.
de Traux de Wardin H; Dermawan JK; Vanoli F; Jiang SC; Singer S; Chi P; Tap W; Wexler LH; Antonescu CR
JCO Precis Oncol; 2024 Apr; 8():e2300597. PubMed ID: 38603649
[TBL] [Abstract] [Full Text] [Related]
4. Investigation of cellular communication and signaling pathways in tumor microenvironment for high tp53-expressing osteosarcoma cells through single-cell RNA sequencing.
Xiong K; Fang Y; Qiu B; Chen C; Huang N; Liang F; Huang C; Lu T; Zheng L; Zhao J; Zhu B
Med Oncol; 2024 Mar; 41(5):93. PubMed ID: 38526643
[TBL] [Abstract] [Full Text] [Related]
5. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract] [Full Text] [Related]
6. treatment and prognostic implications of strong PD-L1 expression in primary hepatic sarcomatoid carcinoma.
Radhakrishnan S; Martin CA; Vij M; Subbiah K; Raju LP; Gowrishankar G; Veldore VH; Kaliamoorthy I; Rammohan A; Rela M
Immunotherapy; 2024 Apr; 16(6):371-379. PubMed ID: 38362631
[TBL] [Abstract] [Full Text] [Related]
7. Targeted inhibition of SCF
Wang J; Ferrena A; Zhang R; Singh S; Viscarret V; Al-Harden W; Aldahamsheh O; Borjihan H; Singla A; Yaguare S; Tingling J; Zi X; Lo Y; Gorlick R; Schwartz EL; Zhao H; Yang R; Geller DS; Zheng D; Hoang BH
Oncogene; 2024 Mar; 43(13):962-975. PubMed ID: 38355807
[TBL] [Abstract] [Full Text] [Related]
8. Regulation of the p53 tumor suppressor gene and the Mcl-2 oncogene expression by an active herbal component delivered through a smart thermo-pH-sensitive PLGA carrier to improve Osteosarcoma treatment.
Akbari P; Taebpour M; Akhlaghi M; Hasan SH; Shahriyari S; Parsaeian M; Haghirosadat BF; Rahdar A; Pandey S
Med Oncol; 2024 Jan; 41(3):68. PubMed ID: 38289404
[TBL] [Abstract] [Full Text] [Related]
9. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
10. Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies.
Recio F; Scalise CB; Loar P; Lumish M; Berman T; Peddada A; Kalashnikova E; Rivero-Hinojosa S; Beisch T; Nicosia B; Farmer T; Dutta P; Malhotra M; ElNaggar AC; Liu MC; Vaccarello L; Holloway RW
Gynecol Oncol; 2024 Mar; 182():63-69. PubMed ID: 38262240
[TBL] [Abstract] [Full Text] [Related]
11. A novel method for detection of pancreatic Ductal Adenocarcinoma using explainable machine learning.
Aslam M; Rajbdad F; Azmat S; Li Z; Boudreaux JP; Thiagarajan R; Yao S; Xu J
Comput Methods Programs Biomed; 2024 Mar; 245():108019. PubMed ID: 38237450
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic and predictive biomarkers in paediatric solid tumours.
Glembocki AI; Somers GR
Pathology; 2024 Mar; 56(2):283-296. PubMed ID: 38216399
[TBL] [Abstract] [Full Text] [Related]
13. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract] [Full Text] [Related]
14. Genetically engineered mouse model of pleomorphic liposarcoma: Immunophenotyping and histologic characterization.
Brown JM; Patel R; Smith-Fry K; Ward M; Oliver T; Jones KB
Neoplasia; 2024 Feb; 48():100956. PubMed ID: 38199172
[TBL] [Abstract] [Full Text] [Related]
15. Activation of HDAC8 Can Suppress the Proliferation of Osteosarcoma Cells via
Wang L; Bai X; Zhang X; Wang X; Chen S; Wu S; Lin L
Ann Clin Lab Sci; 2023 Nov; 53(6):920-930. PubMed ID: 38182151
[TBL] [Abstract] [Full Text] [Related]
16. Sotorasib with panitumumab in chemotherapy-refractory KRAS
Kuboki Y; Fakih M; Strickler J; Yaeger R; Masuishi T; Kim EJ; Bestvina CM; Kopetz S; Falchook GS; Langer C; Krauss J; Puri S; Cardona P; Chan E; Varrieur T; Mukundan L; Anderson A; Tran Q; Hong DS
Nat Med; 2024 Jan; 30(1):265-270. PubMed ID: 38177853
[TBL] [Abstract] [Full Text] [Related]
17. Repurposing Metabolic Inhibitors in the treatment of Colon Adenocarcinoma Patient-Derived Models.
Lee B; Lee C; Moon HM; Jo SY; Jang SJ; Suh YA
Cells; 2023 Dec; 12(24):. PubMed ID: 38132178
[TBL] [Abstract] [Full Text] [Related]
18. Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.
Mochizuki T; Ikegami M; Akiyama T
Cancer Sci; 2024 Feb; 115(2):575-588. PubMed ID: 38115234
[TBL] [Abstract] [Full Text] [Related]
19. Exploration in the Mechanism of Ginsenoside Rg5 for the treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.
Liu MY; Jiang DX; Zhao X; Zhang L; Zhang Y; Liu ZD; Liu RZ; Li HJ; Rong XY; Gao YZ
Orthop Surg; 2024 Feb; 16(2):462-470. PubMed ID: 38086608
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic Factors for Uterine Sarcoma and Carcinosarcoma: Insights from a 10-Year Follow-Up Study.
Kotowicz B; Dańska-Bidzińska A; Fuksiewicz M; Nasierowska-Guttmejer A; Raczkiewicz D; Gujski M; Piątek S; Bidziński M
Med Sci Monit; 2023 Dec; 29():e941562. PubMed ID: 38058118
[TBL] [Abstract] [Full Text] [Related]
[Next]
